All updates
All updates
today 3Nature评分1717 文献与产业新闻评分1515 From Promise to Precision: The Next Chapter of Checkpoint Inhibition
Nature评分1515 Why AI-authorship debates miss a deeper shift in how scholarly knowledge is produced
Nature评分2929 AI-powered medical devices must be tested in real-world settings
The Lancet评分2222 [Comment] A novel and effective treatment for fibrodysplasia ossificans progressiva
文献与产业新闻评分3030 TBXT Challenge points to a prize model for rare-disease targets
文献与产业新闻评分2020 IgA nephropathy, Overton hearing, reverse mergers’ new look — a BioCentury podcast
文献与产业新闻评分2424 Opinion: I discovered a new structure in the heart — just by looking closely
文献与产业新闻评分2828 Opinion: AI is eroding the barriers that kept biological weapons rare
监管与产业动态评分1212 New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption - Fierce Biotech
监管与产业动态评分77 It's a Jungle Out There: Hiring for Resilience in Life Sciences Sales - Fierce Pharma
BioPharma Dive评分1212 Kids shouldn’t have to organize childhood around medicine
BioPharma Dive评分1515 Breakthrough therapies still need builders
文献与产业新闻评分2525 Molecular insights into triazole-based compounds for triple-negative breast cancer treatment
文献与产业新闻评分2525 Cranial Neuropathies-Easy to See, Hard to Diagnose: Toward an Integrated Diagnostic Framework for Rare Conditions
Nature Medicine评分2929 When detecting Ebola is not enough: closing the response interval in DRC
Cancer Cell精选评分5050 The wu wei of brain metastases: When the gift of a pause is also a vulnerability
监管与产业动态评分2626 Cranial Neuropathies-Easy to See, Hard to Diagnose: Toward an Integrated Diagnostic Framework for Rare Conditions
监管与产业动态评分1818 Molecular insights into triazole-based compounds for triple-negative breast cancer treatment
Nature评分3131 Bigger than CRISPR? A guide to the latest genome editors
Nature精选评分3434 China now leads the world in trials for next-gen CAR-T therapies
Nature评分2323 Vaping in childhood has bigger health risks than we’d thought
监管与产业动态评分1212 Signal or noise? > One CRISPR treatment cut “bad” cholesterol in half for a full year - ScienceDaily >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #healthcare #biotech #pharma
监管与产业动态评分1212 Signal or noise? > Gene-Editing Detection Kits Market To 2035: Clinical Trials Drive Growth - News and Statistics - IndexBox >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #healthcare #biotech
监管与产业动态评分77 Signal or noise? > Is uniQure (QURE) Undervalued Or Is Its Gene Therapy Promise Already Priced In? - simplywall.st >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech
监管与产业动态评分77 Signal or noise? > Gene therapy & health equity in Sickle Cell Awareness Month - FOX 5 Atlanta >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #biotech #pharma #healthcare
文献与产业新闻评分1414 Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?
NEJM评分1919 Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy
NEJM评分77 The Mayor
NEJM评分1313 Vaping for Crypto — Smart Devices, Risky Business
NEJM评分1111 Opioid-Settlement Funds — Lessons from Tobacco
文献与产业新闻评分2323 Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma
监管与产业动态评分2727 Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma
The Lancet评分1212 [Correspondence] From isolation to burial: dignity in the Bundibugyo virus disease response
文献与产业新闻评分2323 IgA nephropathy’s formula for continuous innovation
监管与产业动态评分77 Signal or noise? > Reimagining Value-Based Deals Through Risk-Pooling Models - AJMC >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #competitivemarketing #pharma
文献与产业新闻评分1818 Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
文献与产业新闻评分2121 STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
BioPharma Dive评分1717 This week in charts: Novo’s rise and fall and AI biotechs’ big haul